Wedbush analyst David Nierengarten upgraded Karyopharm to Outperform from Neutral based on increased confidence in selinexor's commercial potential in DLBC. In a research note to investors, Nierengarten says he sees current share levels as an attractive entry point for the stock ahead of the topline Phase 2b SADAL readout at ASH. Beyond DLBC, he sees selinexor being approved in multiple myeloma on its April 6, 2019 PDUFA date and is looking forward to additional Phase 2b STORM data at ASH, as well as Phase 1b/2 STOMP data where he will look for additional insights into selinexor's potential in earlier lines of therapy. The analyst has a $19 price target on shares.